Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated reports news around its precision oncology pipeline, including clinical and preclinical programs aimed at genetically and epigenetically defined cancer targets. Recurring updates cover PRT12396, a mutant-selective JAK2V617F inhibitor being developed for certain myeloproliferative neoplasms, and PRT13722, an orally bioavailable selective KAT6A degrader being developed in breast cancer.
Company announcements also address FDA and IND-related developments, preclinical data presentations at oncology and hematology meetings, financial results, investor presentations, executive appointments, and capital-structure activity tied to its Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), announced participation in three healthcare investment conferences. On May 2, CEO Kris Vaddi will engage in a fireside chat at the H. C. Wainwright BioConnect Investor Conference at Nasdaq. The Bank of America Securities 2023 Healthcare Conference will feature Dr. Jane Huang and CFO Laurent Chardonnet in one-on-one meetings on May 10 and 11, with Dr. Huang presenting a fireside chat on May 10 at 4:20 p.m. PT. Lastly, during the JMP Securities Life Sciences Conference on May 15 and 16, Dr. Vaddi and Mr. Chardonnet will hold one-on-one meetings, with Dr. Vaddi participating in a fireside chat on May 15 at noon ET. Prelude's pipeline includes four promising drug candidates targeting key cancer pathways.
Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, announced the presentation of eight abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, occurring from April 14-19 in Orlando, Florida. The research highlights progress in their pipeline, including two clinical abstracts on compounds PRT1419 and PRT2527, which target specific cancer pathways in advanced tumors. Jane Huang, President and CMO, noted the supportive safety and pharmacokinetic profiles for further development in hematological cancers. Additionally, preclinical data on the SMARCA2 degrader program will be presented, alongside favorable data on other candidates such as PRT3645 and PRT3789. This showcases Prelude's commitment to innovative treatment options for cancer patients.
Prelude Therapeutics (Nasdaq: PRLD) reported significant advancements in its clinical pipeline during 2022, highlighting four differentiated compounds in Phase 1 trials. The company aims to present initial data from its PRT2527 and PRT1419 programs at the upcoming AACR Annual Meeting. As of December 31, 2022, Prelude's cash reserves stood at $201.7 million, sufficient to fund operations through Q4 2024. Research and development expenses increased to $92.9 million, while general and administrative costs rose to $30.7 million. The company posted a net loss of $115.4 million for the fiscal year, slightly higher than the previous year.
Prelude Therapeutics (Nasdaq: PRLD) announced a clinical trial collaboration with BeiGene to evaluate its CDK9 inhibitor, PRT2527, alongside BeiGene's BTK inhibitor, zanubrutinib, for treating hematologic malignancies. This collaboration is based on recent evidence showing enhanced efficacy of CDK9 and BTK inhibition in B cell malignancies.
Prelude retains all operational and commercial rights for PRT2527 while BeiGene provides zanubrutinib. PRT2527 is currently undergoing a Phase 1 dose-escalation study for advanced solid tumors and hematologic malignancies, demonstrating potential as a selective and potent treatment option.
Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in the Barclays Global Healthcare Conference in Miami from March 14 to 16, 2023. On March 16 at 9:30 a.m. ET, CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat. One-on-one meetings are scheduled for March 15 and 16.
Prelude focuses on developing innovative drug candidates targeting critical cancer pathways, with a pipeline featuring four candidates: PRT1419, PRT2527, PRT3645, and PRT3789.